DiscoverProject Oncology®Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning

Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning

Update: 2025-09-17
Share

Description

Host: Hallie Blevins, PhD.




Early resistance to hydroxyurea in patients with polycythemia vera (PV) is associated with higher risks of thromboembolic complications, disease progression, and mortality. The PV-AIM study applied machine learning to real-world data and identified simple lab-based predictors that stratify patients by risk, and these findings were later validated in the HU-F-AIM trial. Hear from ReachMD's Dr. Hallie Blevins as she dives into the results and explains implications for optimized therapy and improved long-term outcomes.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning

Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning